An Intervention to Reduce Prolonged Sitting in Police Staff

November 11, 2020 updated by: Marsha Brierley, University of Bedfordshire

A-REST (Activity to Reduce Excessive Sitting Time): a Cluster Randomised Controlled Feasibility Trial to Reduce Prolonged Sitting in Police Staff

The primary aim of this study is to assess the feasibility of an intervention to reduce and break up prolonged sitting time in full-time police staff. The secondary aims of this study are to assess preliminary effects on patterns of sedentary behaviour (number of breaks, number of prolonged sitting bouts, average duration of prolonged sitting bouts, and total prolonged sitting duration), additional measures of sedentary behaviour (total sitting time, standing, and stepping), cardiometabolic risk markers, physiological stress (cortisol levels), physical health (self-report and postural stability), psychological wellbeing and mood, work stress (self-reported), and work performance (job satisfaction and productivity).

Study Overview

Detailed Description

Prolonged sedentary behaviour is associated with a higher incidence of cardiovascular disease and type 2 diabetes. A large proportion of daily sedentary time (sitting) occurs in the workplace. On average, full time office workers spend upwards of 70% of their working day seated with the majority of this time accumulated in sitting bouts ≥ 20 minutes. A recent cross-sectional investigation into the occupational characteristics of over 5,000 British police force employees reported at least 30% identifying as having mainly office-based duties. When trying to reduce prolonged sitting in the workplace, one of the most effective strategies is the use of multi-component interventions. At the present time, sedentary workplace intervention studies in the police are limited.

The primary aim of this study is to assess the feasibility of an intervention to reduce and break up prolonged sitting time at work in full-time police staff. The secondary aims of this study are to assess preliminary effects on sedentary behaviour, cardiometabolic risk markers, physiological stress, physical health, psychological wellbeing and mood, work stress, and work performance.

This has a single-arm, pre-post study design. Participants will receive a multi-component intervention to break up and reduce prolonged sitting including: a presentation/workshop, electronic support, minor environmental modifications, organisational support, and team competition. Assessments will take place at baseline and post-intervention (week 10).

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bedfordshire
      • Bedford, Bedfordshire, United Kingdom, MK41 9EA
        • University of Bedfordfordshire

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • ≥ 0.6 Full Time Equivalent (FTE) work hours
  • Ambulatory
  • Predominantly desk-based (spend on average ≥ 5-h/day seated at work by self-report)
  • Own a smartphone, with ability to keep phone with them during work hours

Exclusion Criteria:

  • Planned absence of two weeks or more during the intervention period
  • Work part time (< 0.6 FTE)
  • Health contraindications to standing and walking
  • Planned relocation to another site, office or workplace
  • Have personal access to an active workstation (sit-stand desk, seat cycle, treadmill desk or similar)
  • Participating simultaneously in another workplace intervention (for sedentary behaviour, physical activity, diet, lifestyle, or combination thereof)
  • Health contraindications to postural stability testing (e.g., injury to the lower extremities in the past six months, dizziness, or epilepsy)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
The intervention group will aim to regularly break up participants' prolonged sitting time with three-minute incidental movement breaks every half hour at work. Support for behaviour change will include a lecture/workshop, electronic prompts, break logging, team competition, health champions, and email support.
3-min breaks every half hour at work

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility - Adherence: Drop-out rates in control and intervention group
Time Frame: From recruitment (typically 4 weeks prior to baseline) up to study completion (typically 12 weeks)
Analyses of drop-out rates (%) in control and intervention group.
From recruitment (typically 4 weeks prior to baseline) up to study completion (typically 12 weeks)
Feasibility - Acceptability: Perceptions of the intervention
Time Frame: At week 11
Asking participants' to qualitatively reflect on the intervention via semi-structured interview.
At week 11

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the number of breaks (sit-stand transitions) from sedentary time per hour (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of sit-stand transitions.
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Change in sitting time accrued in prolonged bouts (≥ 30 minutes) (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of sitting time accrued in prolonged bouts (≥ 30 minutes).
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Change in the average duration (minutes) of prolonged sitting bouts (≥ 30 minutes) (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of the average duration (minutes) of prolonged sitting bouts (≥ 30 minutes).
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Change in the number of prolonged sitting bouts (≥ 30 minutes) (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of the number of prolonged sitting bouts (≥ 30 minutes).
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Change in the total duration (minutes) of sitting time (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of sitting time.
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Change in step count (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of step count.
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Change in total stepping time (in minutes) (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of total stepping time (in minutes).
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Change in total standing time (in minutes) (workplace and daily)
Time Frame: This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Participants will wear a thigh-based accelerometer/inclinometer (ActivPAL3), which provides a well established measure of total standing time (in minutes).
This measure will be assessed at baseline and 10 weeks. At each time point the accelerometer will be worn for 7 days.
Weight (kg)
Time Frame: Baseline and at week 11
Changes in weight via Tanita scale.
Baseline and at week 11
Body mass index (BMI)
Time Frame: Baseline and at week 11
Changes in BMI will be computed by dividing participants' weight (in kilograms) by their height (in metres) squared.
Baseline and at week 11
Waist circumference (cm)
Time Frame: Baseline and at week 11
Changes in waist circumference will be assessed by tape measure.
Baseline and at week 11
Body fat %
Time Frame: Baseline and at week 11
Changes in body fat percentage will be assessed via a bioelectric impedance spectroscopy device.
Baseline and at week 11
Body fat mass (kg)
Time Frame: Baseline and at week 11
Changes in body fat mass via a bioelectric impedance spectroscopy device.
Baseline and at week 11
Lean body mass (kg)
Time Frame: Baseline and at week 11
Changes in lean body mass via a bioelectric impedance spectroscopy device.
Baseline and at week 11
Blood pressure (mmHg)
Time Frame: Baseline and at week 11
Changes in blood pressure measured via electronic sphygmomanometer.
Baseline and at week 11
Fasted blood cholesterol (mg/dL)
Time Frame: Baseline and at week 11
Changes in total, high density lipoprotein (HDL), and low density lipoprotein (LDL) cholesterol measured via fasting blood tests using a Cholestech machine.
Baseline and at week 11
Fasted blood triglycerides (mg/dL)
Time Frame: Baseline and at week 11
Changes in triglycerides measured via fasting blood tests using a Cholestech machine.
Baseline and at week 11
Fasted blood glucose (mg/dL)
Time Frame: Baseline and at week 11
Changes in glucose levels measured via fasting blood tests using a Cholestech machine.
Baseline and at week 11
Salivary cortisol (nmol/L)
Time Frame: Baseline and at week 11. At each time point saliva samples will be collected at 7 time points over the course of one day.
Changes in the cortisol awakening response and diurnal cortisol levels will be assessed via saliva samples (provided by chewing on a cotton swab for 60secs) collected seven times over the course of one day.
Baseline and at week 11. At each time point saliva samples will be collected at 7 time points over the course of one day.
Nordic musculoskeletal questionnaire
Time Frame: Baseline and at week 11
The Nordic musculoskeletal questionnaire is comprised of 40 forced-choice questions pertaining to low back, neck, shoulder and general physical complaints most often experienced in the work setting. A visual diagram aids the viewer by labelling the nine regions of the body referred to in the questionnaire. Acceptable reliability for this tool has been demonstrated.
Baseline and at week 11
Postural sway velocity (mm/s)
Time Frame: Baseline and at week 11
Change in postural sway velocity (bipedal-eyes-open, bipedal-eyes-closed, unipedal-eyes-open, unipedal-eyes-closed) will be evaluated via dynamic plantar pressure sensor (RS Footscan).
Baseline and at week 11
Postural sway range (mm)
Time Frame: Baseline and at week 11
Change in postural sway range (bipedal-eyes-open, bipedal-eyes-closed, unipedal-eyes-open, unipedal-eyes-closed) will be evaluated via dynamic plantar pressure sensor (RS Footscan).
Baseline and at week 11
International Physical Activity Questionnaire short form (IPAQ)
Time Frame: Baseline and at week 11
Changes in self-reported physical activity and total sitting time. The International Physical Activity Questionnaire short form (IPAQ) measures self-reported physical activity and sitting time in the last seven days. Participants are asked to report frequency of participation (0-7 days) and duration of activity on one of those days (in hours and minutes). The IPAQ has demonstrated acceptable reliability and validity in measuring activity in the last seven days.
Baseline and at week 11
Marshall sitting questionnaire
Time Frame: Baseline and at week 11
The Marshall sitting questionnaire has five questions that measure self-reported domain-specific sitting time (hours and minutes) on weekend days and weekdays. This questionnaire has good reliability and validity for sitting time on weekdays and weekend days.
Baseline and at week 11
Warwick-Edinburgh mental well-being scale (WEMWBS)
Time Frame: Baseline and at week 11
The Warwick-Edinburgh mental well-being scale (WEMWBS) is a 14-item questionnaire used to assess various aspects of positive mental health (e.g., "I've been feeling optimistic about the future"). Participants are asked to rate their experience of each wellbeing statement between 1 and 5 (1 = none of the time and 5 = all of the time). Item scores are then combined to provide a total score (between 14 - 70). The higher the score the better the overall mental wellbeing. For intervention purposes, a change in the total score of 3-8 points between two time points may be considered a "meaningful change".
Baseline and at week 11
Positive and negative affect schedule (PANAS)
Time Frame: Baseline and at week 11

Changes in self-reported mood via the positive and negative affect schedule (PANAS) consisting of two 10-item subscales to measure positive and negative affect (i.e., mood). A number of words that describe different feelings and emotions (e.g., "interested", "distressed", "excited") are presented and participants are asked to indicate on a 5-point scale to what extent over the past week they have felt these feelings/emotions (1 = very slightly or not at all and 5 = extremely). These scales are internally consistent with very good convergent and discriminant correlations.

Negative Affect subscale Item scores on the negative affect scale are then combined to provide a total score (between 10 - 50). The higher the score the more negative emotions experienced.

Positive Affect subscale Item scores on the positive affect scale are then combined to provide a total score (between 10 - 50). The higher the score the more positive emotions experienced.

Baseline and at week 11
Operational police stress questionnaire (PSQ-Op)
Time Frame: Baseline and at week 11
Changes in ratings of 20 operational stressors for police (PSQ-Org). Participants will be asked to rate items on "how much stress it has caused you over the past 6 months" using a 7-point Likert scale (1 = no stress at all and 7 = a lot of stress). Item scores are then combined to provide a total score (between 20 - 140). The higher the score the worse the stress level. This instrument has demonstrated acceptable reliability and validity for measuring police-specific occupational stressors.
Baseline and at week 11
Organisational police stress questionnaire (PSQ-Org)
Time Frame: Baseline and at week 11
Changes in ratings of 20 organisational stressors for police (PSQ-Org). Participants will be asked to rate items on "how much stress it has caused you over the past 6 months" using a 7-point Likert scale (1 = no stress at all and 7 = a lot of stress). Item scores are then combined to provide a total score (between 20 - 140). The higher the score the worse the stress level. This instrument has demonstrated acceptable reliability and validity for measuring police-specific occupational stressors.
Baseline and at week 11
Job satisfaction
Time Frame: Baseline and at week 11
Changes in self-reported job satisfaction and will be evaluated via a single-item questionnaire ("How satisfied are you with your job in general?") assessed on a 7-point Likert scale (1 = dissatisfied and 7 = extremely satisfied). A higher score represents more satisfaction with one's job.
Baseline and at week 11
Job performance
Time Frame: Baseline and at week 11
Changes in self-reported job performance will be evaluated via a single-item questionnaire ("How well do you think you have performed in your job recently?") with a 7-point Likert scale (1 = very poorly and 7 = extremely well). A higher score represents a more positive assessment of job performance.
Baseline and at week 11

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Daniel Bailey, PhD, University of Bedfordshire

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 9, 2019

Primary Completion (Actual)

December 20, 2019

Study Completion (Actual)

December 20, 2019

Study Registration Dates

First Submitted

July 29, 2019

First Submitted That Met QC Criteria

August 8, 2019

First Posted (Actual)

August 12, 2019

Study Record Updates

Last Update Posted (Actual)

November 13, 2020

Last Update Submitted That Met QC Criteria

November 11, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Musculoskeletal Pain

Clinical Trials on Breaks

3
Subscribe